source
- Enliven Therapeutics' early-stage study shows 48% major molecular response in CML patientsA targeted therapy from Enliven Therapeutics, ELVN-001, produced major molecular responses in 48% of participants with chronic myeloid leukemia (CML) in a 24‑week, early‑stage trial. The study eval…
- Synthetic lethality hype may spark new wave of biotech mergersThe piece highlights rising enthusiasm for synthetic lethality as a cancer‑treatment strategy, especially after recent data releases. In an early‑stage trial, Tango Therapeutics reported that pati…